ICCC FY 2024 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+51.6% YoY

Gross Profit

$8M30.0% margin

Operating Income

-$2M-6.2% margin

Net Income

-$2M-8.1% margin

EPS (Diluted)

$-0.26

Cash Flow

Operating Cash Flow

$357,903

Free Cash Flow

-$107,822

Stock-Based Comp.

$326,000

Balance Sheet

Total Assets

$45M

Total Liabilities

$18M

Stockholders' Equity

$28M

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$17M	+51.6%
Gross Profit	$8M	$4M	+80.6%
Operating Income	-$2M	-$6M	+71.5%
Net Income	-$2M	-$6M	+62.7%